Baseline characteristics of study cohorts with MPN-BP and de novo AML
| Characteristic . | MPN-BP . | De novo AML . | P . |
|---|---|---|---|
| No. of patients | 177 | 4749 | |
| No. of centers | 73 | 221 | |
| Patient-related | |||
| Age at HCT, median (range), y | <.01* | ||
| Median (min-max) | 59 (40-82) | 54 (40-78) | |
| Age at HCT, n (%), y | <.01† | ||
| 40-49 | 30 (17) | 1658 (35) | |
| 50-59 | 73 (41) | 1894 (40) | |
| 60-69 | 59 (33) | 1077 (23) | |
| ≥70 | 15 (8) | 120 (3) | |
| Sex, n (%) | <.01† | ||
| Male | 116 (66) | 2552 (54) | |
| Female | 61 (34) | 2197 (46) | |
| Karnofsky score, n (%) | <.01† | ||
| 90-100 | 88 (50) | 2888 (61) | |
| <90 | 84 (47) | 1664 (35) | |
| Missing | 5 (3) | 197 (4) | |
| HCT-CI, n (%) | <.01† | ||
| 0 | 33 (19) | 705 (15) | |
| 1-2 | 31 (18) | 736 (15) | |
| ≥3 | 50 (28) | 867 (18) | |
| N/A, before 2007 | 61 (34) | 2377 (50) | |
| Missing | 2 (1) | 64 (1) | |
| Disease-related | |||
| Etiology of MPN at original diagnosis, n (%) | |||
| PV | 46 (26) | 0 (0.0) | |
| ET | 51 (29) | 0 (0.0) | |
| PMF | 60 (34) | 0 (0.20) | |
| MPN-U | 20 (11) | 0 (0.0) | |
| Time between diagnosis of MPN and AML, n (%), y | |||
| Median (min-max) | 3 (0.0-30) | N/A | |
| <2 | 70 (40) | 0 (0.0) | |
| 2-5 | 28 (16) | 0 (0.0) | |
| >5 | 63 (36) | 0 (0.0) | |
| Missing | 16 (9) | 0 (0.0) | |
| WBC at diagnosis, n (%), ×109/L | .08† | ||
| <30 | 121 (68) | 2864 (60) | |
| 30-100 | 31 (18) | 859 (18) | |
| >100 | 9 (5) | 453 (10) | |
| Missing | 16 (9) | 573 (12) | |
| Cytogenetics, n (%) | <.01† | ||
| Favorable | 1 (<1) | 305 (6) | |
| Intermediate | 96 (54) | 2910 (61) | |
| Poor | 67 (38) | 1073 (23) | |
| Not tested | 5 (3) | 134 (3) | |
| Missing | 8 (5) | 327 (7) | |
| Disease status at HCT, n (%) | <.01† | ||
| In remission‡ | 101 (57) | 3511 (74) | |
| Active leukemia§ | 76 (43) | 1238 (26) | |
| Time from diagnosis of AML to HCT, median (min-max), mo | 5 (<1-321) | 6 (<1-215) | <.01* |
| Time from diagnosis of AML to HCT, n (%), mo | <.01† | ||
| <6 | 105 (59) | 2146 (45) | |
| 6-12 | 38 (21) | 1246 (26) | |
| >12 | 34 (19) | 1357 (29) | |
| Therapy-related, n (%) | |||
| Induction therapy | <.01† | ||
| 7+3 ± other | 100 (56) | 2997 (63) | |
| Cytarabine-based | 18 (10) | 233 (5) | |
| Hypomethylating | 7 (4) | 49 (1) | |
| Other | 3 (2) | 212 (4) | |
| No therapy given | 11 (6) | 21 (<1) | |
| Missing | 38 (21) | 1237 (26) | |
| Transplant-related | |||
| Graft source, n (%) | .05† | ||
| Bone marrow | 22 (12) | 864 (18) | |
| Peripheral blood | 155 (88) | 3885 (82) | |
| Donor type, n (%) | .25† | ||
| HLA-identical sibling | 54 (31) | 1774 (37) | |
| Other related | 13 (7) | 282 (6) | |
| Well-matched URD | 83 (47) | 1952 (41) | |
| Partially matched/mismatched URD | 27 (15) | 741 (16) | |
| D-R sex match, n (%) | .05† | ||
| M-M | 76 (43) | 1643 (35) | |
| M-F | 36 (20) | 1257 (26) | |
| F-M | 39 (22) | 891 (19) | |
| F-F | 25 (14) | 922 (19) | |
| Missing | 1 (<1) | 36 (<1) | |
| D-R CMV status, n (%) | .06† | ||
| +/+ | 49 (28) | 1566 (33) | |
| +/− | 13 (7) | 468 (10) | |
| −/+ | 58 (33) | 1489 (31) | |
| −/− | 53 (30) | 1038 (22) | |
| Missing | 4 (2) | 188 (4) | |
| Conditioning regimen, n (%) | .01† | ||
| TBI-MAC | 21 (12) | 971 (20) | |
| Chemo-MAC | 72 (41) | 1912 (40) | |
| RIC/NST | 84 (47) | 1866 (39) | |
| GVHD prophylaxis, n (%) | .39† | ||
| CNI + MMF ± others | 47 (27) | 1091 (23) | |
| CNI + MTX ± others | 99 (56) | 2833 (60) | |
| CNI ± others | 19 (11) | 565 (12) | |
| Post-CY | 10 (6) | 157 (3) | |
| Other | 1 (<1) | 42 (<1) | |
| Missing | 1 (<1) | 61 (1) | |
| In vivo T-cell depletion, n (%) | .64† | ||
| No | 131 (74) | 3440 (72) | |
| Yes | 46 (26) | 1309 (28) | |
| Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .81† | ||
| No | 129 (73) | 3504 (74) | |
| Yes | 46 (26) | 1167 (25) | |
| Missing | 2 (1) | 78 (2) | |
| Year of transplant, n (%) | <.01† | ||
| 2001-2005 | 39 (22) | 1600 (34) | |
| 2006-2010 | 72 (41) | 1958 (41) | |
| 2011-2015 | 66 (37) | 1191 (25) | |
| Follow-up, median (min-max), mo | 71 (14-169) | 78 (1-198) |
| Characteristic . | MPN-BP . | De novo AML . | P . |
|---|---|---|---|
| No. of patients | 177 | 4749 | |
| No. of centers | 73 | 221 | |
| Patient-related | |||
| Age at HCT, median (range), y | <.01* | ||
| Median (min-max) | 59 (40-82) | 54 (40-78) | |
| Age at HCT, n (%), y | <.01† | ||
| 40-49 | 30 (17) | 1658 (35) | |
| 50-59 | 73 (41) | 1894 (40) | |
| 60-69 | 59 (33) | 1077 (23) | |
| ≥70 | 15 (8) | 120 (3) | |
| Sex, n (%) | <.01† | ||
| Male | 116 (66) | 2552 (54) | |
| Female | 61 (34) | 2197 (46) | |
| Karnofsky score, n (%) | <.01† | ||
| 90-100 | 88 (50) | 2888 (61) | |
| <90 | 84 (47) | 1664 (35) | |
| Missing | 5 (3) | 197 (4) | |
| HCT-CI, n (%) | <.01† | ||
| 0 | 33 (19) | 705 (15) | |
| 1-2 | 31 (18) | 736 (15) | |
| ≥3 | 50 (28) | 867 (18) | |
| N/A, before 2007 | 61 (34) | 2377 (50) | |
| Missing | 2 (1) | 64 (1) | |
| Disease-related | |||
| Etiology of MPN at original diagnosis, n (%) | |||
| PV | 46 (26) | 0 (0.0) | |
| ET | 51 (29) | 0 (0.0) | |
| PMF | 60 (34) | 0 (0.20) | |
| MPN-U | 20 (11) | 0 (0.0) | |
| Time between diagnosis of MPN and AML, n (%), y | |||
| Median (min-max) | 3 (0.0-30) | N/A | |
| <2 | 70 (40) | 0 (0.0) | |
| 2-5 | 28 (16) | 0 (0.0) | |
| >5 | 63 (36) | 0 (0.0) | |
| Missing | 16 (9) | 0 (0.0) | |
| WBC at diagnosis, n (%), ×109/L | .08† | ||
| <30 | 121 (68) | 2864 (60) | |
| 30-100 | 31 (18) | 859 (18) | |
| >100 | 9 (5) | 453 (10) | |
| Missing | 16 (9) | 573 (12) | |
| Cytogenetics, n (%) | <.01† | ||
| Favorable | 1 (<1) | 305 (6) | |
| Intermediate | 96 (54) | 2910 (61) | |
| Poor | 67 (38) | 1073 (23) | |
| Not tested | 5 (3) | 134 (3) | |
| Missing | 8 (5) | 327 (7) | |
| Disease status at HCT, n (%) | <.01† | ||
| In remission‡ | 101 (57) | 3511 (74) | |
| Active leukemia§ | 76 (43) | 1238 (26) | |
| Time from diagnosis of AML to HCT, median (min-max), mo | 5 (<1-321) | 6 (<1-215) | <.01* |
| Time from diagnosis of AML to HCT, n (%), mo | <.01† | ||
| <6 | 105 (59) | 2146 (45) | |
| 6-12 | 38 (21) | 1246 (26) | |
| >12 | 34 (19) | 1357 (29) | |
| Therapy-related, n (%) | |||
| Induction therapy | <.01† | ||
| 7+3 ± other | 100 (56) | 2997 (63) | |
| Cytarabine-based | 18 (10) | 233 (5) | |
| Hypomethylating | 7 (4) | 49 (1) | |
| Other | 3 (2) | 212 (4) | |
| No therapy given | 11 (6) | 21 (<1) | |
| Missing | 38 (21) | 1237 (26) | |
| Transplant-related | |||
| Graft source, n (%) | .05† | ||
| Bone marrow | 22 (12) | 864 (18) | |
| Peripheral blood | 155 (88) | 3885 (82) | |
| Donor type, n (%) | .25† | ||
| HLA-identical sibling | 54 (31) | 1774 (37) | |
| Other related | 13 (7) | 282 (6) | |
| Well-matched URD | 83 (47) | 1952 (41) | |
| Partially matched/mismatched URD | 27 (15) | 741 (16) | |
| D-R sex match, n (%) | .05† | ||
| M-M | 76 (43) | 1643 (35) | |
| M-F | 36 (20) | 1257 (26) | |
| F-M | 39 (22) | 891 (19) | |
| F-F | 25 (14) | 922 (19) | |
| Missing | 1 (<1) | 36 (<1) | |
| D-R CMV status, n (%) | .06† | ||
| +/+ | 49 (28) | 1566 (33) | |
| +/− | 13 (7) | 468 (10) | |
| −/+ | 58 (33) | 1489 (31) | |
| −/− | 53 (30) | 1038 (22) | |
| Missing | 4 (2) | 188 (4) | |
| Conditioning regimen, n (%) | .01† | ||
| TBI-MAC | 21 (12) | 971 (20) | |
| Chemo-MAC | 72 (41) | 1912 (40) | |
| RIC/NST | 84 (47) | 1866 (39) | |
| GVHD prophylaxis, n (%) | .39† | ||
| CNI + MMF ± others | 47 (27) | 1091 (23) | |
| CNI + MTX ± others | 99 (56) | 2833 (60) | |
| CNI ± others | 19 (11) | 565 (12) | |
| Post-CY | 10 (6) | 157 (3) | |
| Other | 1 (<1) | 42 (<1) | |
| Missing | 1 (<1) | 61 (1) | |
| In vivo T-cell depletion, n (%) | .64† | ||
| No | 131 (74) | 3440 (72) | |
| Yes | 46 (26) | 1309 (28) | |
| Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .81† | ||
| No | 129 (73) | 3504 (74) | |
| Yes | 46 (26) | 1167 (25) | |
| Missing | 2 (1) | 78 (2) | |
| Year of transplant, n (%) | <.01† | ||
| 2001-2005 | 39 (22) | 1600 (34) | |
| 2006-2010 | 72 (41) | 1958 (41) | |
| 2011-2015 | 66 (37) | 1191 (25) | |
| Follow-up, median (min-max), mo | 71 (14-169) | 78 (1-198) |
CNI, calcineurin inhibitor; Chemo-MAC, chemotherapy-based MAC; CMV, cytomegalovirus; D-R, donor-recipient; F, female; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; M, male; MAC, myeloablative conditioning; max, maximum; min, minimum; MTX, methotrexate; N/A, not applicable; NST, nonmyeloablative allogeneic stem cell transplantation; RIC, reduced-intensity conditioning; TBI-MAC, TBI-based MAC; WBC, white blood cell.
Hypothesis testing: Kruskal-Wallis test.
Hypothesis testing: Pearson χ2 test.
In remission, CR1/CR2 for de novo AML and blasts <5% for MPN-BP and post-MDS AML.
Active leukemia, blasts in bone marrow or peripheral blood ≥5%.